News

The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or

The European Medicines Agency (EMA) approved XYDALBA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. XYDALBA can be administered as either one

Specific financial terms of the agreement have not been disclosed and are not material to Endo. Endo will not have any future royalty or milestone payments to BDSI

The business includes Omega Pharma Belgium, Etixx and Biover, situated in Nazareth, Venecoweg 26 (Belgium). As part of the restructuring plan, Perrigo has agreed to end EuroGenerics’s distribution agreement for

FA is a life-shortening and degenerative neuro-muscular disorder that affects nearly 4,000 to 6,000 people in the US. The placebo-controlled trial, Steadfast, failed to demonstrate that Actimmune therapy resulted

Duke will receive an undisclosed upfront payment from Sermonix, as well as future equity and milestone payments. Sermonix also announced that it secured more than $2 million in a

This decision is supported by the most recent data from the Company's ongoing Phase 1b study evaluating the same "triplet combination" therapy being investigated in the amended Phase

Lucentis (ranibizumab) has now been cleared to treat patients for visual impairment due to CNV associated with causes other than neovascular age-related macular degeneration (nAMD) or secondary to

The study found that patients with ALK+ advanced NSCLC treated with first-line Zykadia (ceritinib) had a median progression-free survival (PFS) of 16.6 months (95% confidence interval [CI]: 12.6, 27.2), compared to